Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- Corporate Authors:
- المصدر:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
- بيانات النشر:
Original Publication: San Francisco, CA : Public Library of Science
- الموضوع:
- نبذة مختصرة :
Background: In Latin America (LA), there is a high incidence rate of breast cancer (BC) in premenopausal women, and the genomic features of these BC remain unknown. Here, we aim to characterize the molecular features of BC in young LA women within the framework of the PRECAMA study, a multicenter population-based case-control study of BC in premenopausal women.
Methods: Pathological tumor tissues were collected from incident cases from four LA countries. Immunohistochemistry (IHC) was performed centrally for ER, PR, HER2, Ki67, EGFR, CK5/6, and p53 protein markers. Targeted deep sequencing was done on genomic DNA extracted from formalin-fixed, paraffin-embedded tumor tissues and their paired blood samples to screen for somatic mutations in eight genes frequently mutated in BC. A subset of samples was analyzed by exome sequencing to identify somatic mutational signatures.
Results: The majority of cases were positive for ER or PR (168/233; 72%), and 21% were triple-negative (TN), mainly of basal type. Most tumors were positive for Ki67 (189/233; 81%). In 126 sequenced cases, TP53 and PIK3CA were the most frequently mutated genes (32.5% and 21.4%, respectively), followed by AKT1 (9.5%). TP53 mutations were more frequent in HER2-enriched and TN IHC subtypes, whereas PIK3CA/AKT1 mutations were more frequent in ER-positive tumors, as expected. Interestingly, a higher proportion of G:C>T:A mutations was observed in TP53 in PRECAMA cases compared with TCGA and METABRIC BC series (27% vs 14%). Exome-wide mutational patterns in 10 TN cases revealed alterations in signal transduction pathways and major contributions of mutational signatures caused by altered DNA repair pathways.
Conclusions: These pilot results on PRECAMA tumors give a preview of the molecular features of premenopausal BC in LA. Although the overall mutation burden was as expected from data in other populations, mutational patterns observed in TP53 and exome-wide suggested possible differences in mutagenic processes giving rise to these tumors compared with other populations. Further -omics analyses of a larger number of cases in the near future will enable the investigation of relationships between these molecular features and risk factors.
Competing Interests: The authors have declared that no competing interests exist.
- References:
Nature. 2012 May 16;486(7403):400-4. (PMID: 22722201)
Nat Rev Cancer. 2004 Mar;4(3):177-83. (PMID: 14993899)
Nat Commun. 2016 May 10;7:11479. (PMID: 27161491)
Cell Rep. 2013 Jan 31;3(1):246-59. (PMID: 23318258)
JAMA Oncol. 2017 Dec 1;3(12):1654-1662. (PMID: 28472234)
BMC Bioinformatics. 2010 Jul 02;11:367. (PMID: 20598126)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
BMC Bioinformatics. 2016 Apr 18;17:170. (PMID: 27091472)
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20. (PMID: 23315928)
Oncogene. 2014 Sep 18;33(38):4675-84. (PMID: 24662814)
Nat Genet. 2013 Sep;45(9):970-6. (PMID: 23852170)
Breast Cancer Res Treat. 2017 Aug;164(3):593-601. (PMID: 28503720)
World J Clin Oncol. 2015 Dec 10;6(6):220-4. (PMID: 26677435)
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9. (PMID: 15016911)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926)
Salud Publica Mex. 2009;51 Suppl 2:s141-6. (PMID: 19967268)
Clin Cancer Res. 2006 Feb 15;12(4):1157-67. (PMID: 16489069)
J Pathol. 2017 May;242(1):10-15. (PMID: 28127763)
BMC Cancer. 2010 Nov 30;10:654. (PMID: 21118481)
Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140)
Cancer Res. 2001 Sep 15;61(18):6679-81. (PMID: 11559534)
IARC Sci Publ. 2004;(157):247-70. (PMID: 15055300)
Hum Mutat. 2016 Sep;37(9):865-76. (PMID: 27328919)
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. (PMID: 20182602)
Breast Cancer Res. 2007;9(3):R30. (PMID: 17504517)
EBioMedicine. 2017 Jun;20:39-49. (PMID: 28551381)
Salud Publica Mex. 2014 Sep-Oct;56(5):547-54. (PMID: 25604300)
Sci Rep. 2014 Mar 27;4:4482. (PMID: 24670820)
Nature. 2012 Apr 04;486(7403):395-9. (PMID: 22495314)
Nucleic Acids Res. 2013 Jan;41(Database issue):D793-800. (PMID: 23143270)
Nat Genet. 2017 Oct;49(10):1476-1486. (PMID: 28825726)
PLoS One. 2015 May 11;10(5):e0126762. (PMID: 25961742)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Cancer. 2011 Aug 15;117(16):3658-69. (PMID: 21387260)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
J Exp Clin Cancer Res. 2017 May 12;36(1):65. (PMID: 28494797)
Breast Cancer Res Treat. 2015 Nov;154(2):275-86. (PMID: 26493064)
Nature. 2015 Jan 22;517(7535):489-92. (PMID: 25363767)
Breast Cancer Res. 2015 Aug 07;17:104. (PMID: 26251034)
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):912-5. (PMID: 20233852)
Nat Methods. 2013 Nov;10(11):1081-2. (PMID: 24037244)
Mutat Res. 2007 May-Jun;635(2-3):105-17. (PMID: 17257890)
Bioinformatics. 2012 Jul 15;28(14):1811-7. (PMID: 22581179)
Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925)
Science. 2014 Jan 10;343(6167):189-193. (PMID: 24336570)
- Grant Information:
001 International WHO_ World Health Organization
- الرقم المعرف:
0 (Biomarkers, Tumor)
0 (TP53 protein, human)
0 (Tumor Suppressor Protein p53)
- الموضوع:
Date Created: 20190118 Date Completed: 20191021 Latest Revision: 20240324
- الموضوع:
20240324
- الرقم المعرف:
PMC6336331
- الرقم المعرف:
10.1371/journal.pone.0210372
- الرقم المعرف:
30653559
No Comments.